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 ABSTRACT 
 
Depression is a significant problem for the managed care system. Antidepressant medication helps 
ameliorate the symptoms of depression yet adherence to medication is known to be poor. The current 
approach to adherence measurement (i.e HEDIS) is limited or lacking. Other methods are used (e.g 
Proportion of Days Covered –PDC) in other chronic diseases to measure adherence. Medication adherence 
is a growing concern for clinicians and other health care stakeholders (e.g. payer) because of the increasing 
evidence that non-adherence is prevalent and places patients at an increased risk for adverse health 
outcomes and higher cost of care.  
We conducted a retrospective cohort study of patients enrolled in a Medicaid plan. For inclusion in 
the study population patients had to meet HEDIS inclusion criteria and PDC criteria respectively. Patients 
included in the HEDIS study’s cohort were adults at least 18 years of age with a new diagnosis of 
depression confirmed by outpatient medication use and an ICD-9 diagnostic code. The upper limit age was 
set at 75 years old in order to maintain the confidential information about the patients. Patients had to meet 
certain enrollment eligibility criteria as well. For the PDC study population patients met the same age 
requirement as for the HEDIS measurement inclusion criteria. Patients included in the study for the PDC 
cohort were not required to have a new diagnosis of depression certified by a diagnostic code; they only 
had to be antidepressant medication users during the study period. We evaluated antidepressant medication 
adherence by applying the HEDIS measures and PDC measures. The measure of effect was the odds ratio 
in separate models. We also applied HEDIS criteria to the PDS cohort to provide a head-to-head 
comparison of the rates of adherence. Adherence was assessed with seven medication classes as 
recommended by HEDIS: Miscellaneous Antidepressants. Monoamine Oxidase Inhibitors (MAOIs). 
Phenylpiperazine Antidepressants. Selective Serotonin-Norepinephrine Reuptake Inhibitors 
Antidepressants (SSNRIs).  Selective Serotonin Reuptake Inhibitors Antidepressants (SSRIs). Tetracyclic 
Antidepressants (TeCAs). and Tricyclic Antidepressants (TCAs). Differences in baseline characteristics 
and the odds of adherence were assessed between the groups for each methodology separately as well as 
patient demographic and health related variables. We constructed multivariate logistic regression models to 
measure the odds of adherence with antidepressant medication for each methodology while controlling for 
potential confounders and assessing for interaction terms. The level of significance and the corresponding 
95% confidence intervals of the odds ratios were presented as well.  
A total of 626 eligible antidepressant users were identified according to the HEDIS criteria, and  
22,351 eligible antidepressant users were identified according to PDC criteria and were evaluated for 
adherence with antidepressant medication. In both study samples patients 50 years and older were 
significantly more likely to be adherent with antidepressant medication than the younger group (<35 years ) 
patients. In both groups patients that had respiratory disease had an increased odds of adherence with 
antidepressant medication relative to patients that were not classified having a respiratory disease. Patients 
that had other mental health diagnoses in addition to depression had a statistically significant increased 
odds of adherence with antidepressant medication relative to patients that did not have such diagnoses. The 
beta coefficient representing the relationship between the antidepressant medication adherence and the 
therapy regimen was positive and statistically significant for both samples. Patients that were using more 
than one drug were significantly more likely to be adherent to antidepressant medication regimen than 
patients that were using only one type of antidepressant drugs.  
Our results implicate older age and comorbid diseases such as respiratory and other mental health 
diseases and polymedication as risk factors associated with better adherence with antidepressant medication 
therapy among Medicaid insured patients. Interventions that strive to improve adherence with 
antidepressant medication therapy should continue to be implemented and evaluated.  
 
 
 
 
 
 
 
iv 
 
ACKNOWLEDGMENTS 
 
I would like to acknowledge and express my sincerest gratitude for the enduring expert guidance and 
support that I have been fortunate to receive from my major professor, Dr. Kogut throughout all my 
master’s program and even before starting it.  
I express my appreciation to Dr Chichester and Professor Marcoux for having served on my 
committee. Their thoughtful questions and comments were valued greatly.   
I am extremely satisfied with the expansive and applicable education I have acquired through my 
experience in the program. I take this opportunity to express my thanks to all the faculty members of the 
program of Pharmacoeconomics & Pharmacoepidemiology for their help and encouragement and for all 
whom, directly or indirectly, have lent their helping hand in my academic journey.  
   
 
 
 
 
 
 
 
 
 
 
 
 
 
v 
 
PREFACE 
The standard format was used in preparation of this thesis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
vi 
 
 
 
TABLE OF CONTENTS 
 
           
ABSTRACT .............................................................................................................................................. ii 
ACKNOWLEDGMENTS ........................................................................................................................ iv 
PREFACE ................................................................................................................................................. v 
TABLE OF CONTENTS ......................................................................................................................... vi 
LIST OF TABLES .................................................................................................................................. vii 
LIST OF FIGURES ................................................................................................................................ viii 
CHAPTER 1 .............................................................................................................................................. 1 
INTRODUCTION ..................................................................................................................................... 1 
CHAPTER 2 .............................................................................................................................................. 6 
METHODOLOGY .................................................................................................................................... 6 
CHAPTER 3 ............................................................................................................................................ 11 
RESULTS ............................................................................................................................................... 11 
CHAPTER 4 ............................................................................................................................................ 18 
DISCUSSION ......................................................................................................................................... 18 
CHAPTER 5 ............................................................................................................................................ 22 
LIMITATIONS AND CONCLUSION ................................................................................................... 22 
LIST OF REFERENCES ........................................................................................................................ 34 
BIBLIOGRAPHY………………………………………………………………….……………………41
vii 
 
LIST OF TABLES 
 
 
 
TABLE           PAGE  
Table 1. Baseline characteristics of patients for HEDIS and PDC methodologies  ………………………27 
Table 2. Descriptive statistics. Adherence results for HEDIS and PDC methodologies……….……... ….28 
Table 3.  Likelihood of adherence associated with antidepressant medication use for  
                HEDIS methodology. Univariate logistic regression analyses   …………………………..........29 
Table 4.  Likelihood of adherence associated with antidepressant medication use for  
                PDC methodology. Univariate logistic regression analyses   ………………………….……....30 
Table 5. Univariate logistic regression reduced model for the HEDIS methodology.  
               Likelihood of antidepressant medication adherence according to selected characteristics ………31 
Table 6. Univariate logistic regression reduced model for the PDC methodology.  
               Likelihood of antidepressant medication adherence according to selected characteristic………..32 
 
 
 
 
 
 
 
 
 
 
 
viii 
 
LIST OF FIGURES 
 
FIGURE          PAGE 
Figure 1. Eligibility flowchart: HEDIS application of inclusion and exclusion criteria.………………..25 
Figure 2. Eligibility flowchart: PDC application of inclusion and exclusion criteria..………………….26 
Figure 3. Correlation between continuous adherence measures comparing HEDIS method and PDC   
                adherence calculation method applied to HEDIS cohort………..…………… ………………33 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 
 
CHAPTER 1 
 
INTRODUCTION 
 
Medication adherence is a growing concern for clinicians, and other health system stakeholders 
(e.g. payer) because of the increasing evidence that non-adherence is prevalent and associated with adverse 
outcomes and higher cost of care.
1
 Adherence to a medication regimen is generally defined as the extent to 
which patients take medication as prescribed by their health care providers.
2
  There are many different 
methods for assessing adherence to medication. While there is no consensus about a golden standard for 
measuring medication adherence, numerous subjective and objective medication adherence methods have 
been developed. Oesterberg et al
3
 categorized these methods as either direct or indirect. Direct methods 
include directly observed therapy, measurement of the level of the medicine or metabolite in the blood, and 
measurement of the biological marker in the blood.
3
 Indirect methods of adherence assessment include 
patient questionnaires, self reports, pill counts, rates of prescription refills, assessment of the patient’s 
clinical response, electronic medication monitors, measurements of the psychological markers and patient 
diaries.
3
 
The American Psychiatric Association defines 2 phases of antidepressant treatment: acute phase 
and continuation phase. The current Practice Guideline for the Treatment of Patients with Major 
Depressive Disorder recommends pharmacological treatment for each phase to reduce the risk of relapse.  
Patients having a successful acute phase treatment (adherence over 4-8 weeks) are encouraged to continue 
treatment with antidepressant agents for at least 4 to 9 months.  Moreover, for patients that had multiple 
episodes of depression, further maintenance treatment is recommended for at least one year.
3
 
An ideal measure would evaluate adherence for all patients with depression. Unfortunately, unlike 
other chronic diseases, no measures of medication adherence among chronic users of antidepressants have 
been developed. The Pharmacy Quality Alliance (PQA) recommends using a proportion of days covered 
(PDC) measure for calculating adherence for chronic users of medications for conditions such as diabetes 
and dyslipidemia.  Their measures are endorsed by the National Quality Forum (NQF). The PDC measure 
calculates the percentage of patients that are taking the prescribed medications from a particular drug class 
2 
 
that exceed an 80% adherence benchmark. The Medication Possession Ratio (MPR) is another metric that 
measures medication adherence, yet this measure is considered inferior to the PDC because MPR is a mere 
summation of the day supply, and does not consider multiple therapies. The PDC measure offers a more 
conservative estimate of the medication adherence since it allows looking at each day in the designated 
time period to determine whether an individual has one or more dispensed study drugs. As a proportion, the 
PDC always ranges between 0 and 1.  Typically, an 80% (0.8) threshold is applied to indicate good or poor 
adherence, with higher thresholds set for some therapies (e.g. 90% for antiretrovirals).
4
 
Depression is one of the most common disorders and a leading cause for disability worldwide. 
Almost 50% of the U.S population has experienced at least one psychiatric disorder in their lifetime.
5
 The 
lifetime prevalence of major depressive disorder is reported to be as high as 17% and the 12-month 
prevalence is 5%-9%.
6,7
  The World Health Organization (WHO) considers major depressive disorder one  
of the most debilitating diseases to society. Its negative outcomes include suicide, substantial impairment, 
lower quality of life, increased health care utilization and cost, and adverse impact on employment 
productivity.
8
 It is anticipated that major depressive disorder (MDD) will be the second leading cause of 
disability worldwide by 2020
9
  with a lifetime risk of 7% - 12% for men and 20%-25% for women.
9
  
 Depression is a serious public problem, particularly among people with low income. Low socio-
economic status is associated with a higher prevalence of depression. Moreover, the duration of new 
episodes of depression are longer in people with a low socio-economic level.
10
 According to data from the 
National Health and Nutrition Examination Survey (2009-2012) persons living below poverty level are 
nearly 2½ times more likely to have depression than those at or below poverty level.
11
  
 The incidence of depression is rising and the costs are escalating. People that have depression 
cannot enjoy a fulfilled life because they experience sadness, a sense of isolation and feeling like they are a 
burden. Depressed people are 30 times more likely to commit suicide and each year in U.S. approximately 
41.000 individuals complete suicide.
12
  
 Depression impacts the academic development of a person, the marriage perspective and an 
average loss of $10,400/year in income by the time the person reaches 50 years of age.
13
 Depressed people 
are 7 times more likely to be unemployed.
8
 According to Smith JP et al (2010) a person that suffers from 
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depression has a loss of 20% in potential income, and a lifetime loss for each family who has a depressed 
family member of $300,000.
14
  
 From the employer point of view depression is a big concern also. The employer is affected by the 
missed days of work (absenteeism) and the reduced productivity (presenteeism) of individuals with MDD. 
According to data from the National Health and Nutrition Examination Survey (2009-2012) almost 43% of 
individuals with severe depressive symptoms reported serious difficulties in work, home and social 
activities. The rate of difficulty in work, home or social related activities, increased with the severity of 
depression.
11
  
The consequences of untreated depression or inadequately treated depression are significant, 
therefore adherence to antidepressant medication is crucial. Response to drug therapy occurs predominantly 
in patients who are strictly adherent to antidepressant medication regimens. Most patients experience good 
outcomes with appropriate antidepressants taken for the appropriate period of time. Patients must be closely 
monitored during the acute phase (first three months) and the initial continuation phase (the first six to nine 
months) of treatment for necessary drug dosage adjustments. Measuring adherence is important to make 
sure that patients comply with provider recommendations for a good outcome and a reduced economic 
burden on health care system. The antidepressant therapy must be coupled with the appropriate form of 
psychological therapy. 
 Antidepressant medications are the standard approach for treating depression. According to the 
Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial, depressive disorder is 
challenging to treat.
14
 STAR*D is the largest study of its kind. The results demonstrated that after exposure 
to four different levels of medication intervention options, approximately one-third of the patients in this 
study failed to achieve remission.
14
 Also, approximately 50% of the patients in this trial prematurely 
discontinued antidepressant therapy for a number of different reasons, including patient-related (e.g. side 
effects, misperception about medication), and clinician-related factors (e.g. poor instruction by the clinician 
about the medication, lack of follow-up care). Depression itself is a condition that causes patients to  have 
difficulty following the medication regimen, yet they can have the greatest potential to benefit from 
treatment adherence.
15
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 Currently, there are more than 20 antidepressant medications available worldwide, and they are 
used singularly or in combination with other antidepressants to treat the disabling affects of depression for 
many patients. 
 According to IMS Health National Prescription Audit PLUS, in 2010 antidepressants were the 
second most commonly prescribed medication, second to drugs to lower cholesterol. Approximately 254 
million antidepressant prescriptions were written in 2010, resulting in nearly $ 10 billion in costs.
16
 Eleven 
percent of Americans aged 12 years and over take antidepressant medication and more than 60% of patients 
have taken therapy for 2 years or longer, with 14% having taken the medication for 10 years or more.
11
 For 
most patients, the course of major depressive disorder (MDD) is recurrent or chronic. The goal of 
antidepressant treatment is the full remission of symptoms and prevention of relapse. Remission of 
symptoms is related to improved functioning and prognosis.
17
 Antidepressants are recommended to be 
continued for at least 4 months beyond the initial symptom resolution. However, reported levels of non-
adherence have been consistently high and this remains a serious concern.
18
 Thus, a majority of 
antidepressant users are chronic users of these medications, and  as in other chronic diseases such as 
diabetes and hypertension, the health system must direct resources towards promoting patient adherence 
with prescribed chronic therapies.  
 The National Committee for Quality Assurance (NCQA) is a private standards-setting 
organization which aims to improve the quality of health care and reduce the overall burden of illness. To 
evaluate antidepressant adherence, NCQA uses the Antidepressant Medication Management (AMM) 
measure from the Health Plan Employer Data and Information Set (HEDIS) standardized performance 
measurement tool. HEDIS is a tool used by more than 90% of American health plans to measure 
performance on important dimensions of care, including medication adherence. The HEDIS measure 
focuses on newly diagnosed cases of depression, thus this measure is limited because it omits the majority 
of the patients that are chronic users of antidepressants. The question that arises is how is adherence 
measured for patients that use antidepressants chronically?  
 Another organization that has as a mission to improve quality of medication management is the 
Pharmacy Quality Alliance (PQA). Among the quality measures developed by the Pharmacy Quality 
Alliance (PQA), three quality measures are related to measuring medication adherence for chronic diseases 
5 
 
such as diabetes, hypertension and cholesterol. The PQA adherence measures are endorsed by the National 
Quality Forum (NQF) and are currently used by Centers for Medicare and Medicaid Services (CMS) 
Medicare Part D plans.  
 The PQA identified medication adherence as an important component of medication-use quality 
and endorsed the proportion of days covered (PDC) as standard method for calculating medication 
adherence across prescription drug plans and pharmacies.
4
  
 
Purpose and  Hypothesis 
The purpose of this study was to investigate the suitability of the PDC approach applied to 
antidepressant adherence, in comparison with the HEDIS AMM measure. We sought to determine if the 
percentage of patients identified as adherent with antidepressant medication according to the HEDIS 
(AMM) specifications was similar to the percentage of patients identified as adherent with antidepressant 
medication according to the PDC specifications during the chronic phase of treatment. In patients with a 
confirmed diagnosis of depression (HEDIS) we calculated adherence with antidepressant treatment 
according to the HEDIS specifications for chronic phase of adherence. Adherence was calculated for 
patients that are users of antidepressant medication in the PDC group as well using 80% threshold standard 
to the PDC methodology. Furthermore, we applied the HEDIS inclusion criteria to the PDC population to 
determine the correlation between HEDIS and PDC adherence measurement methodologies in a unified 
sample. Additionally, we evaluated several factors as predictors of adherence for both measures.  
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CHAPTER 2 
 
METHODOLOGY 
 
The study was conducted as a retrospective cohort study using health care claims data describing 
pharmacy utilization for a period spanning July 1, 2013-September 30, 2014. The data for this research 
represent a sample of Medicaid recipients. These data contained information on enrollment and 
demographics, as well as pharmacy and medical claims for approximately 40,000 enrollees utilizing 
antidepressant medication.  
 
HEDIS methodology inclusion and exclusion criteria.   
 Patients were at least 18 years of age as of July 1, 2013 and continuously enrolled for at least 180 
days of a 231 day period between the period of July 1, 2013 to September 30, 2014. Patients older than 75 
years of age were excluded from the study in order to maintain the confidentiality of subjects. All patients 
were confirmed to have a diagnostic code for depression. International classification of disease ninth 
edition (ICD-9) codes from the 2014 Healthcare Effectiveness Data and Information Set (HEDIS)
19
  were 
used to identify the presence of any code indicative of depression or a depression related complication 
(Appendix D). Also patients had to have a diagnosis of depression in an inpatient, outpatient, emergency 
department, intensive outpatient or partial hospitalization setting during the 60 days prior of the starting of 
medication through 60 days after the Index Prescription Start Date (IPSD). All patients were confirmed to 
have used a medication for treatment of depression or a depression related disease, defined as the presence 
of a claim for any oral or injectable antidepressant agent during each patient’s continuous enrollment 
period.  Medication use was evaluated 105 days prior to the IPSD with seven medication classes (Appendix 
E) in order to test the negative medication history (NMH). Patients that had a prescription during the NMH 
period were excluded from the study, thus providing a sample of newly treated patients.   
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PDC methodology inclusion and exclusion criteria. 
 Patients were at least 18 years of age as of July 1, 2013 and continuously enrolled for 365 days 
during the study period. Patients older than 75 years of age were excluded from the study in order to 
maintain the confidentiality of subjects.  No ICD-9 codes for a diagnostic of depression were required for 
the PDC methodology inclusion criteria. Patients that used any of the antidepressant medications from the 
seven classes (Appendix E) were included in the study.  Patients were also required to have at least 91 days 
between the index medication and the end of the study period.  
  
Defining Adherence 
 Eligibility for the HEDIS methodology required that all patients have at least one antidepressant 
claim during the index period associated with an ICD-9 diagnostic of depression 60 days prior or after the 
first prescription. This will ensure that the patients has a new diagnosis of depression according to HEDIS 
requirements. Patient must not have an antidepressant claim during a 105 days period prior to the index 
date. Patient with a claim during the negative medication history were excluded from the study population. 
The continuation phase of the treatment lasts 231 days, during which a patient needs to fill a sufficient 
number of antidepressant prescriptions to provide medication for at least 180 days. Medication gap due to 
washout or refill can total a maximum of 51 days during the 231-day period. Adherence was determined as 
the proportion between the days supply of dispensing divided by the days of follow up during the chronic 
phase  (231 days) . Patients were classified as adherent if they remained on antidepressant medication for at 
least 180 days (6 months) of the 231 days in the period.  
 For the PDC methodology, all patients were required to have at least one antidepressant claim 
during the index period. The index date should occur at least 91 days prior to the end of the study period. 
Adherence was also evaluated as a dichotomous variable and calculated as the proportion between the days 
supply of dispensing during the study period divided by the number of days between the fill days and the 
end of the study period. According to the Pharmacy Quality Alliance (PQA) patients will be considered 
adherent to their medication if the PDC is equal to or exceeds 80% and non-adherent if the PDC is less than 
80%. Adherence with antidepressant medication was evaluated separately for the two methodologies as the 
inclusion criteria for the measures were different, yielding different samples. 
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Independent Variables 
Age:  We created three age groups, approximately the youngest, middle aged, and older patients in the 
population. Most older adults 65 years old or older receive their prescription drugs benefit through 
Medicare Part D plans, and were not included in this study.  
Gender: Analyzed as a dichotomous variable. 
Individual Comorbid Diseases: The presence of diabetes, cardiovascular, respiratory and mental health 
diseases (other than depression) was identified during the entire study period using the ICD-9 codes from 
the HEDIS 2015 (Appendix A, B, C, D). The diabetes disease variable comprised codes for diabetes with 
and without complications and also codes for the drug therapeutic class.(Appendix A). The cardiovascular 
disease variable comprised codes for congestive heart failure, coronary artery disease, myocardial 
infarction, and other forms of ischemic and non-ischemic cardiovascular disease (Appendix B). Respiratory 
disease comprised codes for bronchitis, emphysema and asthma. Mental health disorders comprised codes 
for schizophrenia, bipolar disorder, paranoia, psychosis, anxiety, autism, panic disorder, personality 
disorders, acute stress disorders, impulse control disorders, anger/ aggression disorders, attention deficit 
disorder, and attention hyperactivity deficit disorder. These four conditions were selected based on high 
prevalence and high health expenditure. 
Physician care visits:  We analyzed if patients visited a physician providing a basis for qualifying patients 
as seeing a medical doctor or not visiting a physician during the follow-up period. 
Medication regimen: The antidepressant medication regimen was calculated as the number of unique 
antidepressant types dispensed during the study period providing a basis to classify patients as users of 
antidepressant monotherapy or polytherapy.   
 
Statistical Analysis 
 The analysis of the data was performed using Statistical Analysis Software Version 9.4 (SAS® 
Version 9.4). The Pearson Chi-Square test was used to assess differences between groups (within each 
measure separately).  Continuous variables were compared using t-tests for independent samples. The 
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relationship between HEDIS/PDC and adherence, are presented as frequencies and percentages of patients 
that were adherent to antidepressant medication according to each characteristic. Results with a P-value 
<=0.05 were considered statistically significant while p-values <0.2 were used in selecting variables for 
inclusion in the multivariate model. Univariate logistic regression was used to assess each individual 
variable and the results with the P-values are  presented with odds ratios and corresponding 95% 
confidence intervals. Multivariate logistic regression was used to assess the relationship between the 
independent variables describing patient and provider characteristics, and the dependent variable of 
medication adherence, measured by the AMM and PDC methods. Antidepressant medication adherence 
was the risk factor of interest, with all other independent variables considered potential confounders of the 
relationship with the dependable variable of adherence. These models were created using a stepwise 
approach removing the least statistically significant interaction terms at each step.  Two-way interactions 
were assessed using a hierarchical approach.  The likelihood ratio test was used to compare models in order 
to evaluate if the inclusion of interaction terms improved the model fit. The difference in the -2 log statistic 
between the full model and the reduced model was compared to the corresponding Chi-square statistic with 
the degrees of freedom equal to the difference in the number of terms in the models. Multivariable 
colinearity was assessed for all the possible confounders for each model (both for HEDIS and PDC 
measures). The adherence beta estimate for the full model with all variables was used as the standard for 
comparison.  The final multivariate model for both HEDIS and PDC measures contained all important 
variables for model inclusion. The Akanke Information Criterion statistic and the Hosmer-Lemeshow  
goodness of fit test were used to assess the fit of the final models. 
A third sample was created by applying the inclusion and exclusion criteria for PDC methodology 
to patients that met the HEDIS inclusion and exclusion criteria. The sample was analyzed to determine if 
there is a correlation between measuring adherence with antidepressant medication using HEDIS and PDC 
methodology using a continuous measure of adherence. 
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Resources required 
 The journal articles, clinical guidelines and other important information necessary for the 
successful completion of this research were obtained using the University library or interlibrary exchange 
services, PubMed through the College of Pharmacy, or other professional services available on World 
Wide Web such as government information policy on HEDIS and PDC measures. Data used in this study 
were provided by Major Professor Stephen Kogut. This study was approved by URI Institutional Review 
Board.  Analyses of the data were conducted using SAS® Version 9.4 -University of Rhode Island. 
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CHAPTER 3 
 
RESULTS 
 
 The two separate samples were created after applying the inclusion/exclusion criteria for both 
HEDIS and PDC methods that were subsequently statistically analyzed. The main difference between the 
samples created is that patients included in the HEDIS sample have a new diagnosis of depression 
documented by an ICD-9 code, whereas the patients in the PDC sample are simply antidepressant users 
irrespective of diagnosis. 
 
Application of inclusion and exclusion criteria for HEDIS methodology 
 The final cohort comprised a total of 626 Medicaid patients that met all the inclusion and 
exclusion criteria for HEDIS methodology (Figure 1). The initial cohort was comprised of 32,052 patients 
initially from which a number of 15,056 patients were excluded because they did not met the enrollment 
criteria and had no prescription for an antidepressant drug during the study period. Further 22,370 patients 
were excluded from the cohort for (1) not having a diagnosis of depression according to a ICD-9 code,  (2)  
not being prescribed an antidepressant agent during the intake period and (3) not meeting the eligibility 
criteria according to HEDIS requirements.  
 
Application of inclusion and exclusion criteria for PDC methodology 
The final cohort was comprised of 22,351 patients (Figure 2). Initially a total number of 34,481 
patients were identified as using an antidepressant medication agent. After selecting only the patients that 
had an antidepressant prescription during the study period, 1,352 patients were excluded.  After applying 
the continuous enrollment criteria another 1,591 patients were excluded from the sample.  Further, 5,190 
patients were excluded from the sample because they (1) did not use an antidepressant agent included in the 
study criteria and (2) their index medication was not greater than 91 days prior to the end of the study 
period. 
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HEDIS Baseline Characteristics 
The analytic cohort for the HEDIS measure was comprised of 626 patients (Table 1). Patients in 
this cohort had a new diagnosis of depression documented by o a ICD-9 code. The mean (standard 
deviation [SD]) age of enrolled patients was 37.59 [12.16]. The majority of the cohort was female 
representing 79.52% of  the cohort sample and only 20.48% were male . The prevalence of diabetes, 
cardiovascular, respiratory and mental health disease was different between groups. Patient with diabetes 
comprised 7.35% of the HEDIS group. Patients with cardiovascular disease made up 13.42% of the HEDIS 
group, patients with respiratory disease made up 6.55%, whereas patients with mental health disorders 
made up 33.07% of this sample. In terms of the health care utilization, 27.48% of HEDIS patients were 
hospitalized during the study period and 74.60% visited a psychiatrist. Variability existed with regard to the 
therapeutic regimen, with 57.99% of patients taking a single antidepressant drug during the study period. 
Approximately sixty-six percent of the patients were prescribed a selective serotonin reuptake inhibitor 
(SSRI) medication, 12.62% of the patients were prescribed trazodone, while 8.31% of the patients were 
prescribed bupropion. Selective norepinephrine reuptake inhibitors (SNRIs) agents and tricyclic (TCAs) 
antidepressants were prescribed to 4.95% of the patients and 4.63%, respectively. Patients that were 
prescribed mirtazapine accounted for 3.35% of the sample.  
 
PDC Baseline Characteristics 
 The analytic cohort for PDC measure was comprised of  22,351 patients (Table 1). Patients in this 
cohort are users of antidepressant drugs and did not have a diagnostic of depression according to an ICD-9 
code. The mean (standard deviation [SD]) age of enrolled patients was 42.76 [12.42]. The majority of the 
cohort was female representing 72.14%% of the cohort sample, and only 27.86% were males. The 
prevalence of diabetes, cardiovascular, respiratory and mental health disease was different between groups. 
Patient with diabetes made up 11.69%  of the  group. Patients with cardiovascular disease made up 14.45% 
while patients with respiratory disease made up 6.17% of the  group. Other mental health disease was 
present in 21.28% of the PDC group. In terms of the health care utilization, 16.71% of patients were 
hospitalized during the study period and  36.54% had  a physician visit. Therapeutic regimens varied and 
69.50% of patients took  a single antidepressant drug during the study period. Approximately 66% percent 
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of the patients were prescribed a serotonin reuptake inhibitor (SSRI) medication, while 11.91% of the 
patients were prescribed trazodone, and 10.04% of the patients were prescribed bupropion. Selective 
norepinephrine reuptake inhibitors (SNRIs) agents and tricyclic (TCAs) antidepressants were prescribed to 
patients in 7.49%  and  9.98% of the cases,  respectively . Patients that were using mirtazapine accounted 
for 3.62% of the PDC sample.  
 
Adherence with antidepressant medication according to HEDIS methodology 
 The bivariate relationships between the dependent variable, adherence with antidepressant 
medication according to HEDIS methodology, and all other variables are presented as frequencies and 
percentages in Table 2. Patients were considered adherent if they met or exceeded the HEDIS adherence 
threshold of 180 of 231 days else they were considered non-adherent. The overall adherence for the HEDIS 
measure was 37.38% with 234 of the 626 patients taking their medication as prescribed by their provider. 
Significant differences between adherent and non-adherent patients existed across all three age stratum (P-
value <0.001). The highest level of adherence was registered among older patients in the over 50 age 
group, and the lowest level of non-adherence (28.67%) was among the younger group of individuals (less 
than 35 years of age). Approximately thirty-eight percent of females were adherent to the antidepressant 
medication regimen compared with 35.16% of males, without a statistical significant difference (P-value= 
0.6091). Among patients that had a diagnosis of diabetes, 45.65% were adherent to the antidepressant 
medication therapy, but without significant difference from patients without diabetes (P-value=0.2678). 
Patients with cardiovascular disease were adherent to antidepressant medication therapy at 44.05%, which 
did not differ from the rate among patients without cardiovascular disease (P-value=0.1838).  Patients with 
respiratory disease were more frequently adherent (56.10%) than patients without this condition (P-value= 
0.0123). Adherence among patients with other mental health disease (42.03%) did not differ statistically in 
terms of adherence with antidepressant medication compared with the patients that did not have diagnoses 
for other mental health conditions (P-value= 0.0958). Related to health care utilization, 39.40% of patients 
that visited a psychiatric practitioner and 39.79% of hospitalized patients, were adherent to the medication 
regimen; however,  neither of these comparisons yielded statistically significant differences (P-value= 
0.0874 and P-value=0.9264, respectively).  Adherence rates varied among the antidepressant medication 
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drug classes with no statistical difference between the adherent and non-adherent groups. Adherence 
among patients utilizing antidepressant polytherapy was 49.43%, which was statistically significantly 
greater than adherence among users of monotherapy (P-value<0.001). 
 
 Adherence with antidepressant medication according to PDC methodology. 
The bivariate relationship between the dependent variable, adherence with antidepressant 
medication according to the PDC methodology, and all other variables are presented as frequencies and 
percentages in Table 2. Patients were considered adherent if they met or exceeded the adherence threshold 
of 80%, else they were considered non-adherent. The overall adherence rate according to the PDC measure 
was 50.37% with 11,259 of 22,351 patients taking their medication as prescribed by their provider. 
Significant differences between adherent and non-adherent patients existed across all three age stratum (P-
value<0.001). The highest level of adherence was registered among older patients in the >50 years of age 
group, 61.85% compared with 37.12% in the youngest age group (P-value<0.001).  The proportion of  
female  patients that were adherent to the antidepressant medication regimen compared to the proportion of 
males that adherent was  50.00% to 51.33% , without a statistically significant difference (P-value= 
0.0758).  In terms of the comorbid conditions, all the differences between the presence/absence of the 
condition with adherence rates were statistically significant with a P-value<0.001. Among patients that had 
a diagnosis of diabetes, 61.35% were adherent to the antidepressant medication therapy, which exceeded 
adherence rates for patients without diabetes (P-value <0.001). Patients with cardiovascular disease were 
adherent to antidepressant medication therapy at 58.85%, which exceeded adherence among patients 
without cardiovascular disease (P-value <0.001).  Patients with respiratory disease (62.19%) and other 
mental health diseases (54.38%)  that were adherent to the antidepressant medication therapy differed  
statistically  significant from those without these conditions (37.81% and 45.62%, respectively) with P-
values<0.001. Related to health care utilization, the group of patients that visited a psychiatric practitioner 
during the follow up period were adherent in a proportion 56.01%, which exceeded the rate among patients 
lacking such visits (P-value <0.001). Among patients with at least 1 hospitalization during the period,  
51.75% were adherent to the medication regimen; the adherence rate among patients that were not 
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hospitalized was not statistically significantly different (P-value=0.0645). Users of SNRIs and trazodone 
were more frequently adherent than users of SSRIs. TCAs, and mirtazapine (P-value<0.001).    
 
 Univariate Logistic Regression Analyses for HEDIS and PDC methodologies 
Univariate logistic regression analyses were performed for both methodologies in order to test the 
association of each explanatory variable separately with the outcome (adherence with antidepressant 
medication) in order to identify variables for inclusion in the multivariate analyses. We also excluded the 
variables from the further analysis that did not show significant association with the outcome (adherence 
with antidepressant medication) on their own as they are not likely to be associated with the outcome after 
adjusting for other variables. The results of the univariate logistic regression for all the variables considered 
in the analysis are presented in Table 3.  For both methodologies, the middle and older age groups had 
statistically significant positive beta coefficients that showed the association of age with the outcome 
(adherence with antidepressant medication). The Odds Ratios were >1 for both age groups for both 
methodologies, having 95% confidence intervals that did not overlap unity.  A statistically significant 
positive association [Odds (95% CI)] between the respiratory disease and the outcome was found for both 
methodologies with [OR 2.265 (1.159 - 4.293)] for HEDIS cohort and [1.672 (1.494 - 1.870)] for PDC 
cohort, with P-values<0.001. 
 
Likelihood of antidepressant medication adherence according to HEDIS selected characteristics 
The results of the multivariate logistic regression analysis of the effect of antidepressant therapy 
on  medication adherence according to HEDIS methodology  are presented in Table 5. Collinearity was not 
found between any of the independent variables assessed for the inclusion into the model. Interaction 
between variables was assessed as well to decide whether any interaction terms should be included into the 
final model. No significant interactions were found. The likelihood ratio chi-square was used to decide on 
the best model and was calculated by subtracting  the -2log likelihood of the model with the variable from 
the nested model (Nested model= the model without the variable). The Hosmer-Lemeshow goodness of fit 
test showed that that the model was an appropriate one (p > 0.05)  The beta coefficients representing the 
relationship between antidepressant medication adherence and  age group 35-49, and group age older than 
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50 years, were statistically significant (0.3190 and  0.9463 respectively [P-value<0.001]). Patients 50 years 
and older  were  significantly more likely to be adherent with antidepressant medication than those less than 
35 years old (OR 2.576 [95% CI 1.626 – 4.083]). Patients that had respiratory disease had an increased 
odds of adherence with antidepressant medication  relative to patients that were not-adherent and suffered 
from a respiratory disease (OR 1.745 [95% CI 0.894 – 3.406]). Patients that had a mental health disease 
had increased odds of adherence with antidepressant medication relative to patients that were not-adherent 
and had the same comorbid condition (OR 1.379 [95% CI 0.964 – 1.973]). The beta coefficient 
representing the relationship between the antidepressant medication adherence and the therapy regimen was 
positive and statistically significant (0.3213 [P-value<0.001]. Patients that were using more than one 
antidepressant were significantly more likely to be adherent to antidepressant medication regimen than 
patients that were using only one type of antidepressant drugs  (OR 2.214 [95% CI 1.570 – 3.121]).  
 
Likelihood of antidepressant medication adherence according to PDC selected characteristics 
The results of the multivariate logistic regression analysis of the effect of antidepressant therapy 
on medication adherence according to PDC methodology are presented in Table 6. Collinearity was not 
found between any of the independent variables assessed for the inclusion into the model. Interaction 
between variables was assessed as well to decide whether any  interaction terms should be  included into 
the final model. The  interactions found between the independent variables are discussed in the limitations 
section of the paper, as the interactions terms were not suited to be included in the final model. The 
likelihood ratio chi-square was used to decide on  the best model and was calculated by subtracting  the -
2log likelihood of the model with the variable from the nested model. The goodness of fit test showed that 
that the model was an appropriate one. The beta coefficients representing the relationship between 
antidepressant medication adherence and  age group 35-49, and group age older than 50 years, were 
statistically significant (0.5484 and  1.0101 respectively [P-value<0.001]). Patients 50 years and older  
were significantly more likely to be adherent with antidepressant medication than the  less than 35 years old 
patients (OR 2.746 [95% CI 2.564 – 2.940]).   
The beta coefficient representing the relationship between adherence with antidepressant 
medication and  diabetes was statistically significant (0.5051 [P-value<0.001]). Patients that had  diabetes  
17 
 
were significantly more likely to be adherent with antidepressant medication  than  patients that did not 
have diabetes  (OR 1.657 [95% CI 1.524 – 1.802]). The beta coefficient representing the relationship 
between adherence with antidepressant medication and  cardiovascular disease was statistically significant 
(0.4003 [P-value<0.001]). Patients that had  cardiovascular  disease  were significantly more likely to be 
adherent with antidepressant medication  than  patients that did not have cardiovascular disease  (OR 1.492 
[95% CI 1.384 - 1.609]). Patients that had respiratory disease had a statistically increased odds of 
adherence with antidepressant medication relative to patients that were not-adherent and suffered from a 
respiratory disease (OR 1.672 [95% CI 1.594 – 1.870]). The beta coefficient representing the relationship 
between the adherence with antidepressant medication and other mental health disease was statistically 
significant (0.2042 [P-value<0.001]. Patients that had a mental health disease had a statistically increased 
odds of adherence with antidepressant medication  relative to patients that were not-adherent and had the 
same comorbid condition (OR 1.227 [95% CI 1.150 - 1.308]). Patients that were using more than one 
antidepressant were significantly more likely to be adherent to antidepressant medication regimen than 
patients that were using only one type of antidepressant drugs  (OR 4.807 [95% CI 4.509 - 5.125]). Patients 
that used  SNRIs were statistically more likely to be adherent to antidepressant regimen compared with 
those that were not taking an SNRI drug (OR 1.740 [95% CI 0.789 - 0.878]).  
 
Correlation between adherence with antidepressant medication using  HEDIS and adherence with 
antidepressant medication using PDC methodology 
The final cohort comprised a total of 626 Medicaid patients that met all the inclusion and 
exclusion criteria for HEDIS methodology applied to the PDC sample. The sample was analyzed to 
determine if there is a correlation between measuring adherence with antidepressant medication using 
HEDIS and PDC methodology. We calculated the correlation coefficient of the two variables and we found 
that the two methodologies are highly positively correlated with a correlation coefficient of 0.95. This 
means that the two variables are closely correlated and that  if we measure  adherence with antidepressant 
medication according to  HEDIS methodology for patients that meet the PDC criteria, in 95% of the cases 
they will be found adherent.  A correlation matrix plot is presented in Figure 3.  
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CHAPTER 4 
 
DISCUSSION 
 
Major depressive disorder is a prevalent and debilitating disease among the U.S adult population. 
Effective treatment and adherence with antidepressant medication regimen is essential for optimal 
therapeutic outcome and for lower economic implications. Depression is a chronic disease, and many 
patients will be taking medication for long periods of time, maybe lifelong. According to the World Health 
Organization (2003) “adherence is the extent to which a person’s behavior in taking medication 
corresponds with agreed recommendations from the health care provider”2 and that adherence is a 
multidimensional phenomenon determined by the interplay of five sets of factors: socio economic, health 
care system, condition related, therapy related and  patient related. Moreover, WHO stresses the fact that 
the consequences of non-adherence are may be very serious, and if non-adherence were a disease, it could 
be termed an “epidemic”.2  
Efforts are being made by institutions, clinicians and professional organizations to determine the 
most effective interventions to improve patient’s adherence.  While medication adherence for chronic 
diseases such as diabetes and hypertension have well established measures, adherence with antidepressant 
medication is only measured for new diagnosed patients, leaving aside the chronic users of antidepressants.  
Further research is needed to better address how medication adherence is measured among patients with 
chronic depression.  
 The present study investigated if there is a difference between the percentage of patients identified 
as adherent with antidepressant medication according to AMM specifications and the percentage of patients 
identified as adherent with antidepressant medication according to the PDC specifications during the 
chronic phases of treatment. It was hypothesized that the predictors of non-adherence will be similar for the 
HEDIS and PDC methodologies. The effect of older age on adherence with antidepressant medication 
[Odds ratio (95% CI)] was consistent between the two groups, as age was a significant risk factor for non-
adherence with antidepressant medication for both HEDIS [OR 2.576 [95% CI 1.626 – 4.083])] and PDC 
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patients  (OR 2.746 [95% CI 2.564 – 2.940]). This is possibly explained by the fact that older people take 
more medication as compared to the younger patients, hence more prone to be considered adherent.   
 
As expected, the effect of polymedication on adherence [Beta estimate (P-value)] was  consistent 
between the two analyzed groups [0.3213 (P-value<0.001)] for HEDIS and [1.5701(P-value<0.001)] for 
PDC we considered in our analysis that no more than two drugs were prescribed for same medical 
condition and coded polytherapy by looking at the drugs filled in the same day. We excluded from our 
analysis one of the drugs refilled in the same day during our study period. A limitation of the HEDIS 
method is that it does not adequately discern between combination therapy and medication switch. Thus, 
patients using more than more type of antidepressant are more likely to be classified as adherent. The 
univariate models for HEDIS methodology [Odds ratios (95% CI)] supported to lack of direct association 
between diabetes and cardiovascular diseases and adherence with antidepressant medication [OR 1.447 
(95% CI 0.971 -  2.648)] and [OR 1.379 (95% CI 0.866 – 2.195)] respectively. The multivariate model for 
PDC methodology [Odds ratios (95% CI)]  supported the association between adherence with 
antidepressant medication and chronic comorbid conditions  such as diabetes and cardiovascular  diseases 
[OR 1.675 (95% CI 1.524 – 1.802)] and [OR 1.492 (95% CI 1.384 – 1.609)] respectively. The latter finding 
aligns with the findings of a study by Katon et al
20
 concerning adherence with antidepressant drug therapy 
in patients with evidence of diabetes or cardiovascular disease, or both. Patients adherent with 
antidepressant medication were more likely to be adherent to comorbid therapy versus those non-adherent 
to antidepressant drug therapy (Odds ratio [OR], 2.13 for cardiovascular, [OR] 1.85 for diabetes, [OR] 
1.45, P-values<0.001 for both).
20   
 Factors associated with medication adherence are dependent upon the characteristics of the patient 
population, the medication class and data source evaluated. According to the World Health Organization 
(2003) “adherence is the extent to which a person’s behavior in taking medication corresponds with agreed 
recommendations from the health care provider”2 and that adherence is a multidimensional phenomenon 
determined by the interplay of five sets of factors: socio economic, health care system, condition related, 
therapy related and  patient related.  A study by Akincgil el al
21
 looked at adherence with antidepressant 
medication among privately insured patients diagnosed with depression. The study used medical and 
pharmacy claims data for 4312 subjects that were continuously enrolled in the health plan with a new 
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diagnostic of depression and who initiated antidepressant treatment. Treatment adherence was assessed for 
acute phase and continuation phase using the Health Plan Employer Data and Information Set (HEDIS) 
quality measures for outpatient depression care. The results showed that 51% of patients were adherent 
through acute phase.  Older age and higher economic status were associated with better adherence.  
Alcohol and other substance abuse predicted lower acute-phase adherence (OR=0.49 and OR=0.72 
respectively) for patients having two or more cardiovascular/metabolic conditions (OR=0.65), and for those 
who started treatment with an older generation antidepressant (OR=0.69). The presence of follow up visits 
from a psychiatrist positively influenced adherence. (OR=1.19).  Among patient adherent during the acute 
phase, 41.5% remained adherent during the continuation phase. Adherence was significantly lower for 
Health Maintenance Organizations (HMO) enrollees compared with indemnity enrollees (OR=0.62).
22
 
According to Jeon-Slaughter
22
 low level income combined with health insurance status and race/ethnicity, 
predict non-adherence to antidepressant treatment. The study extracted data from the National Comorbidity 
Survey-Replication (NCR-R) and the sample study comprised 280 adults between age 18 and 64 who were 
diagnosed with  major depressive episode according to DSM-IV at some point during their lifetime and 
medicated with SSRIs in the past 12 months. The study results stated that African Americans were at 
higher risk of medication noncompliance that whites  (Odds ratio, 4.53) and major depressive episode 
comorbidity was positively associated with medication noncompliance (Odds ratio, 4.52).
23
 
 Strategies to improve adherence with antidepressant medication therapy involve pharmacists, 
educational interventions involving physicians, nurses, different tools and structures that health plans may 
use to improve depression care. Finley et al
23
 assessed the effect of collaborative care model with emphasis 
on the clinical pharmacist in providing drug management and treatment follow up to patients with 
depression. They compared the outcomes of subjects treated in the collaborative model (75 patients) with 
subjects receiving usual care (50 patients). After 6 months, the intervention group demonstrated a 
significantly higher drug adherence rate than the control group (67% vs 48%, odds ratio 2.17, 95% 
confidence interval 1.04 -4.51, p=0.038).
23
 Another study by Hoffman  et al
24
 evaluated the impact of mail-
based physician and member educational interventions on patients adherence with antidepressant 
medication. The study was a prospective randomized controlled one that followed 9564 patients over 6 
months after filling a new prescription of antidepressant medication. A pharmacy claim claims database 
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was used to identify patients and track medication adherence. Practitioners were randomly assigned to 
intervention and control group. Patient assignment was linked to their physician’s assignment. After 
adjusting the variables, the intervention statistically significant impacted the adherence [95% CI (1.003 – 
1.197) p<0.01] proving that a monthly mail-based educational intervention program can positively 
influence patient adherence to therapy.
24
  
Correlation between the two methodologies proved that adherence with antidepressant medication 
can be measured using the PDC method used for measuring adherence with medication for chronic 
diseases.  
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CHAPTER 5 
 
LIMITATIONS AND CONCLUSIONS 
 
 The present study utilized a retrospective cohort design with variables derived from data based 
claims of insured patients in a Medicaid state program. Because of the nature of the data we lack 
information on race/ethnicity, disease severity, social support of perceived stigma of patients with 
depression. Adherence is a problem that touches more than one level and poor adherence can be influenced 
by factors such as knowledge, attitudes, skills, environment of the patient and providers’ practices.  Due to 
the retrospective, not-randomized study design and the use of claims data we couldn’t analyze all the 
variables that might have influenced adherence with antidepressant medication regimen. Because we 
captured only comorbid disease states through ICD-9 coding only during the study period, we might have 
underestimated the comorbid disease prevalence. There is a potential for misclassification surrounding the 
outcome (adherence) considering that patients that were prescribed two drugs on the same day were 
classified as using polytherapy. Some interactions were found between age and therapeutic regimen.  
Adults over 35 years old were more likely [OR (95% CI)] to use more than one drug and be adherent more 
often compared with the younger patients;  the age group 35-49 years  [1.415 (1.205 – 1.661), the age 
group older than 50 years [1.642 (1369 – 1.970)] with statistical P-value<0.001. Also, when more drugs 
were dispensed, the SSRIs were more likely to be prescribed [0.402 (0.318 – 0.509)] with a P-value<0.001. 
We derived measures of adherence from claims data rather than observing actual medication use. It is 
possible that patients picked up medication but then did not proceed to take it, resulting in a 
misclassification of baseline adherence.  
Our study is believed to be the first evaluating the correlation between the measuring adherence 
with antidepressant medication according to HEDIS methodology and PDC methodology, so there was no 
evidence in the literature to support our findings. The generalization of our results is limited and 
confirmation of our results is to be warranted.   
 In conclusion, in both cohorts age (over 35 years) was found to be a risk factor for adherence with 
antidepressant medication for both groups.  Patients that had respiratory disease had an increased odds of 
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adherence with antidepressant medication relative to patients that did not have a respiratory disease. 
Patients that had a mental health disease had increased odds of adherence with antidepressant medication 
relative to patients that did not have these comorbid conditions. Patients that were using more than one 
drug were significantly more likely to be adherent to antidepressant medication regimen than patients that 
were using only one type of antidepressant drugs. 
 The methodologies of measuring adherence are closely correlated and that  if we measure  
adherence with antidepressant medication according to  HEDIS methodology for patients that meet the 
PDC criteria, in 95% of the cases  they will be found adherent. The findings of this study suggest that PDC 
methodology may be a suitable method of measuring adherence with antidepressant medication. The larger 
sample size for PDC methodology gives it some advantages over the HEDIS methodology sample: (1)  is 
more representative of the population being analyzed and the results can be generalized to larger population 
with confidence, (2) greater accuracy of the results, (3) diversity and outliers are captured and  observing 
them would give a more accurate picture of the characteristics of the population, dividing the sample into 
smaller sample groups can give deeper and valuable information about the population.   
Patients using antidepressants should be adherent regardless of indication for use. Because HEDIS 
methodology limits the measuring of adherence only to new patients with and ICD-9 diagnosis of 
depression, a large percent of patients that might have another diagnosis/ or no diagnosis at all, are not 
considered for adherence measurement.  Another aspect is represented by the fact that there is currently no 
measure in place to quantify adherence with antidepressant medication for chronic depression.  
 HEDIS methodology of measuring adherence with antidepressant medication has some 
limitations. Antidepressants may be prescribed by non-psychiatrists to treat medical disorders in the 
absence of a psychiatric diagnosis According to US Department of  Health and Human Services 2008
25
,  23 
% of U.S. adults had a mental health problem treated in the past year  by a general medical provider 
(physician, nurse, or other health professional), 16 % by a non-psychiatrist mental health specialist, 12 % 
by a psychiatrist, 8 % by a human services provider, and 7 % by a complementary and alternative medical 
provider. Not all of these professions might be a as expert in diagnosis and treating depression.
25
  
 Other limitation of HEDIS is that looking back 105 days might not be long enough and thus some 
cases are not new users; it does not exclude patients that were misdiagnosed with depression; it relies on 
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pharmacy dispensing records which may not represent medication actually taken by the patient. People 
might be dually enrolled during the study period they might be eligible for Medicare, but not have the 
Medicaid part. Another limitation of the approach is the duration of therapy. Not all patients need to use 
antidepressant medication indefinitely, regardless of diagnosis. This means that some patients may be 
considered non-adherent with antidepressant medication when applying the method, although the patient 
may have legitimately ended the treatment at the provider’s recommendation.  
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Figure 1.  Eligibility Flowchart: Application of Inclusion and Exclusion Criteria for HEDIS 
methodology 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
38,052  unique patient IDs 
 
No prescription claim for an 
antidepressant 
(exclude 4,659 ) 
 
N = 33,393  
 
No continuous enrollment  
 (exclude 10,397) 
 
N = 22,996  
 
Not using antidepressant medication 
during the intake period 
(exclude 18,160) 
 
 (exclude xxx) 
 N = 4,836  
 
Absence of  ICD-9 code for depression  
                    (exclude 3,917) 
 
N = 919  
 
Do not have the eligibility criteria  
                   (exclude 293) 
 
N = 626  
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Figure 2.  Eligibility criteria for Inclusion and Exclusion Criteria for PDC methodology 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
34,481 Patients using antidepressant 
medication 
 
No prescription during the study period  
 (exclude 1,352) 
 
 (exclude xxx) 
 
N=33,129 
 
No continuous enrollment  
 (exclude 1,591) 
 
 (exclude xxx) 
 
N=31,538 
 
Not using the antidepressant included 
in the study design  
 (exclude 2,871 ) 
 
 (exclude xxx) 
 N=28,667 
Not being enrolled at least 91 days 
prior to end of the study period 
 (exclude 6,316) 
 
 (exclude xxx) 
 N=22,351 
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Table 1.  Baseline Characteristics of  Patients Identified for Antidepressant Adherence Measurement 
Using  HEDIS
1
 and PDC
2
 methodology 
 
Characteristic HEDIS
1 
 N = 626 
%     (n) 
PDC
2
  
 N = 22,351 
%     (n) 
P value 
  
Age, years 
Mean Age [SD] 
37.59 [12.16] 42.76 [12.42]  
 
 
 < 0.001 
 
%     (n) %     (n) 
Age < 35 44.73 (280)  29.43 (6579) 
35 <  Age <49 35.30 (221) 37.06 (8242) 
50 ≤ Age  19.97 (125) 33.50 (7488) 
% (n)  
Gender %     (n) %     (n)                      
< 0.001 
 
Male 20.48 (128) 27.86 (6228) 
Female 79.52  (497) 72.14 (16123) 
  
Comorbid Disease Present  Absent Present Absent P value 
%     (n) %     (n) 
        Diabetes 7.35 (46) 92.65 (580) 11.69 (2613) 88.31 (19738) 0.008 
        
Cardiovascular 
13.42 (84) 85.58 (542) 14.45 (3230) 85.55 (19121) 0.468 
        Respiratory 6.55 (41) 93.45 (585) 6.17 (1178) 20973 (93.83) 0.694 
        Mental Health 33.07 (207) 66.93 (419) 21.28 (4757) 78.92  (17594) <0.001 
  
Health Care 
Utilization 
Present Absent Present Absent P value 
%     (n)                  %     (n) 
Psychiatric visits 74.60 (467) 25.40 (159) 36.54 (8168) 63.46 (14183) < 0.001 
Hospitalization 27.48 (172) 72.52 (454) 16.71 (3735) 83.29 (18616) <0.001 
  
Therapy Regimen Present Absent Present Absent P value 
%     (n) %     (n) 
Monotherapy 57.99 (363) 42.01 (263) 69.50 (15534) 30.50 (6817) <0.001 
SSRI
3 
65.81 (412) 34.19 (214) 56.81 (12643) 43.19 (9611) <0.001 
SNRI
4 
4.95 (31) 95.05 (595) 7.49 (1667) 92.51 (28587)        0.017 
Trazodone 12.62 (79) 87.38 (547) 11.91 (2651)  88.09 (19603)  0.590 
TCA
5 
4.63 (29) 95.37 (597) 9.98 (2221)  90.02 (20033) <0.001 
Bupropion 8.31 (52) 91.69 (574) 10.04 (2235) 20019 (89.96) 0.153 
Mirtazapine 3.35 (21) 96.65 (605) 3.62 (805) 96.38 (21449) 0.728 
1
HEDIS - patients have a diagnosis of depression 
2
PDC- includes all users of antidepressants irrespective of diagnosis 
3
SSRI-Selective Serotonin Reuptake Inhibitors Antidepressants,  
4
SNRI-Selective Serotonin-Norepinephrine Reuptake Inhibitors Antidepressants,  
5
TCA-Tricyclic antidepressants 
 
*  
P value is significant. Pearson chi-square test was used for all categorical comparisons and  the 
independent  t-test for continuous variables with equal variance  
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Table 2.  Descriptive statistics. Adherence results for HEDIS and PDC methodologies 
Characteristics HEDIS
1
  
N = 626 
%     (n) 
PDC
2 
 N =22.351 
%     (n) 
 
P Value
 
 
 
1
Overall 
adherence  
37.38%  (234) 50.37 %  (11,259)  
 
 
Age, years 
Adherent 
 
Non-adherent  Adherent Non-adherent  
% (n) P Value % (n) P Value 
Age < 35 28.67 (80) 71.33 (199) <0.001
* 
37. 12 (2442) 62.88 (4137) <0.001
*
 
35 <  Age <49 38.91  (86) 38. 91 (135) 50.53 (4186) 49. 47 (4098) 
50 ≤ Age  53. 60  (67) 46. 40 (58) 61. 85 (4631) 38. 15 (2857) 
 
Gender %(n) P Value %  (n) P Value 
Male 35. 16 (45) 64. 84 (83) 0.6091 51.33 (3197) 48.67 (3031) 0.0758 
Female 37.95 (189) 62.05 (309) 50.00 (8062) 50.00 (8061) 
 
Comorbid 
Disease
 
%  (n) P Value %  (n) P Value 
Diabetes 45.65 (21) 54.35 (25) 0.2678 61.35  (1603) 38.65  (1010) <0.001
* 
Cardiovascular 44.05  (37) 55.95 (47) 0.1838 58.85 (1901) 41.15  (1329) <0.001
*
 
Respiratory 56.10  (23) 43.90 (18) 0.0123 62.19  (857) 37.81  (521) <0.001
*
 
Mental Health 42.03  (87) 57.97 (120) 0.0958 54.38  (2587) 45.62 (2170) <0.001
*
 
 
Health Care 
Utilization 
%  (n) P Value %  (n) P Value 
Psychiatric visits 39.40 (184) 60.60 (283) 0.0874 56.00 (4574) 44.00 (3594) <0.001
* 
Hospitalization 37.79  (65) 62.21 (107) 0.9264 8.65  (1933) 8.06 (1802) 0.0645 
 
Therapy 
Regimen 
%  (n) P Value %  (n) P Value 
Polytherapy 49.43 (130) 50.57 (133) <0.001
* 
75.66 (5158) 24.34 (1659) <0.001
*
 
SSRI
3
 34.47 (142) 65.53 (270) 0.0450
* 
48.41 (6121) 51.59  (6522) <0.001
*
 
SNRI
4 
58.06  (18) 41.94 (13) 0.210 62.93 (1049) 37.07 (618) <0.001
*
 
Trazodone   36.71 (29) 63.29  (50) 1.000 56.21 (1490) 43.79  (1161) <0.001
*
 
TCA
5 
44.83 (13) 55.17 (16) 0.4342 42.73 (949) 57.27 (1272) <0.001
*
 
Bupropion 44.23 (23) 55.77 (29) 0.2975 51.01 (1140) 48.99  (1095) 0.5471 
Mirtazapine 38.10 (8) 61.90 (13) 1.000 44.10 (355) 63.90 (450) 0.0016 
1
HEDIS - patients have a diagnosis of depression 
2
PDC- includes all users of antidepressants irrespective of diagnosis 
3
SSRI-Selective Serotonin Reuptake Inhibitors Antidepressants,  
4
SNRI-Selective Serotonin-Norepinephrine Reuptake Inhibitors Antidepressants,  
5
TCA-Tricyclic antidepressants 
Patients will be considered adherent to their medication if PDC >80% and non-adherent if PDC <80%
.
 
*  
P value is significant.  
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Table 3.  Likelihood of adherence associated with antidepressant use for HEDIS
1
 methodology.  
Univariate Logistic Regression Analyses 
 
Characteristic Beta  
Coefficient 
Odds Ratio              95%  
Confidence Interval   
 
 
Age, years 
  
   
   
Age < 35 - - Reference 
35 <  Age <49 0.4478* 1.565* 1.077 - 2.275 
50 ≤ Age  1.0430* 2.838* 1.834 - 4.389 
 
Gender    
Female - - Reference 
Male -0.1206 0.886 0.591 - 1.330 
 
Comorbid Disease
 
   
Diabetes 0.3697 1.447 0.971 - 2.648 
Cardiovascular 0.3211 1.379 0.866 - 2.195 
Respiratory 0.8174* 2.265* 1.159 - 4.293 
Mental Health 0.2938 1.341 0.954 - 1.887 
 
Health Care Utilization    
Psychiatric visits 0.3488 1.417 0.967 - 2.078 
Hospitalization 0.0242 1.024 0.713 - 1.472 
 
Therapy Regimen    
Polytherapy 08895* 2.434* 1.746 - 3.392 
SSRI
2 
-0.3604 0.697* 0.497 - 0.978 
SNRI
3 
0.8875 2.429* 1.167 - 5.054 
Trazodone 0.0328 0.968 0.593 - 1.578 
TCA
4 
0.3238 1.382 0.653 - 2.928 
Bupropion 0.3107 1.364 0.769 - 1.300 
Mirtazapine 0.0316 1.032 0.421 - 2.528 
1
HEDIS - patients have a diagnosis of depression 
2
SSRI-Selective Serotonin Reuptake Inhibitors Antidepressants,  
3
SNRI-Selective Serotonin-Norepinephrine Reuptake Inhibitors Antidepressants,  
4
TCA-Tricyclic antidepressants 
 
*  
P value<=0.2 is significant.  
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Table 4.  Likelihood of adherence associated with antidepressant medication use for PDC
1
 
methodology. Univariate Logistic Regression Analyses 
 
Characteristic Beta  
Coefficient 
Odds Ratio              95%  
Confidence Interval   
 
 
Age, years 
  
   
   
Age < 35 - - Reference 
35 <  Age <49 0.5484* 1.730* 1.620 - 1.849 
50 ≤ Age  1.0101* 2.746*  2.564 -  2.940 
 
Gender    
Female - - Reference 
Male 0.0532 1.055 0.995 - 1.118 
 
Comorbid Disease
 
   
Diabetes 0.5051* 1.657* 1.524 - 1.802 
Cardiovascular 0.4003* 1.492* 1.384 - 1.609 
Respiratory 0.5138* 1.672 1.494 - 1.870 
Mental Health 0.2042* 1.227*  1.150  - 1.308 
 
Health Care Utilization    
Psychiatric visits 0.3559* 1.427 1.351 - 1.508 
Hospitalization 0.0663 1.069 0.996 -  1.146 
 
Therapy Regimen    
Polytherapy 1.5701* 4.807* 4.509 - 5.125 
SSRI
2 
-0.1835* 0.832* 0.789 - 0.878 
SNRI
3 
0.5539* 1.740* 1.570 - 1.929 
Trazodone 0.2651* 1.304* 1.201 - 1.415 
TCA
4 
-0.3428* 0.710 0.650 - 0.776 
Bupropion 0.0272 1.028 0.942 - 1.121 
Mirtazapine 0.2296* 1.258 1.092 - 1.405 
1
PDC- includes all users of antidepressants irrespective of diagnosis 
2
SSRI-Selective Serotonin Reuptake Inhibitors Antidepressants,  
3
SNRI-Selective Serotonin-Norepinephrine Reuptake Inhibitors Antidepressants,  
4
TCA-Tricyclic antidepressants 
 
*  
P value<=0.2 is significant for model selection.  
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Table 5.  Fitted Reduced Model for HEDIS
1
 methodology.  Likelihood of antidepressant medication 
adherence according to selected characteristics 
 
Characteristic Beta  
Coefficient 
Odds Ratio              95%  
Confidence Interval   
 
Age, years  
Age < 35 - - Reference 
35 <  Age <49 0.3190* 1.376 0.932 - 2.030 
50 ≤ Age  0.9463* 2.576 1.626 - 4.083 
 
Gender    
Female - - Reference 
Male -0.3017 0.740 0.481 – 1.138 
 
Comorbid Disease
 
   
Respiratory 0.5567* 1.745 0.894 - 3.406 
Mental Health 0.3213 1.379 0.964 - 1.973 
 
Therapy Regimen    
Polytherapy 0.3213* 2.214 1.570 - 3.121 
1
HEDIS - patients have a diagnosis of depression 
*  
P < 0.05 
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Table 6.  Fitted Reduced Model for PDC
1
 methodology.  Likelihood of antidepressant medication 
adherence according to selected characteristics 
 
Characteristic Beta  
Coefficient 
Odds Ratio              95%  
Confidence Interval   
 
Age, years  
Age < 35 - - Reference 
35 <  Age <49 0.5484* 1.730         1.620 - 1.849 
50 ≤ Age  1.0101* 2.746 2.564 -  2.940 
 
Gender    
Female - - Reference 
Male 0.0532 1.055 0.995 - 1.118 
 
Comorbid Disease
 
   
Diabetes 0.5051* 1.657 1.524 -1.802 
Cardiovascular 0.4003* 1.492 1.384 - 1.609 
Respiratory 0.5138* 1.672 1.594 - 1.870 
Mental Health 0.2042* 1.227 1.150 - 1.308 
 
Therapy Regimen    
Polytherapy 1.5701* 4.807 4.509 - 5.125 
SNRI
2 
0.5339* 1.740 1.570 - 1.929 
SSRI
3 
-0.1835* 0.832 0.789 - 0.878 
1
PDC- includes all users of antidepressants irrespective of diagnosis 
2
SSRI-Selective Serotonin Reuptake Inhibitors Antidepressants,  
3
SNRI-Selective Serotonin-Norepinephrine Reuptake Inhibitors Antidepressants,  
 
*  
P < 0.05  
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Figure 3.  Correlation between continuous adherence measures comparing HEDIS method and PDC 
adherence calculation method applied to HEDIS cohort 
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APPENDIX A 
ICD-9 CODES TO IDENTIFY DIABETES 
 
25000  25001  25002  25003  25010  25011  25012  25013  25020  25021  25022  25023 25030  25031  
25032  25033  25040  25041  25042  25043  25050  25051  25052  25053  25060  25061  25062  25063  
25070  25071  25072  25073  25080  25081  25082  25083  25090  25091  25092  25093  3572    36201  
36202  36203  36204  36205  36206  36207  36641  64801  64802  64803  64804 
 
DRUG THERAPEUTIC CLASS TO IDENTIFY DIABETES 
C4G C4F C4K C4L C4N C4R C4S C4T 
-Diabetes mellitus type I 
-Diabetes mellitus type II 
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APPENDIX B 
ICD-9 CODES TO IDENTIFY CARDIOVASCULAR DISEASE 
 
401    40100   4010   4011    4019    425     4250   4251   42511   42518    4352    4253   4254   4255   4257 
4258 4259  428      4280     4281   4282    42820  42821  42822  42823   4283    42830   42831  42832   
42833   4284 42840  42841   42842   42843   4289    413    4130    41300   41310   41390   41000   41001   
41002   41010   41011 41012  41020   41021   41022   41030   41031   41032   41040    41041   41042   
41050   41051    41052    41060 41061   41062    41070    41071    41080   41081   41082   41090   41091   
41092   41100  41110   41181    41189 41200    41300     41310     41390    41401    41403   41404  41405   
41406   41407    41410    41411  41412    41419 41480   41490   42800   42810    42820    42821   42822   
42823   42830   42831    42832   42833   42840      42841 42842   42843   42890    40201    40211    40291   
40401   40411    40491   40403   40413   40493   39891 
 
-High blood pressure 
-Hyperpiesia 
-Hypertensive heart disease 
-Malignant hypertensive heart disease 
-Benign hypertensive heart disease 
-Unspecified hypertensive heart disease 
-Acute myocarditis 
-Acute percarditis 
-Heart failure 
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APPENDIX C 
ICD-9 CODES TO IDENTITY RESPIRATORY DISEASE  
 
493     4930    29300    49301    49302    4931     49310    49311    49312   4938    49381   49382   4939   
49390 49391   49392   4932   49320   49321   49322   496   4960   49600   49100   466   491   4910   49100   
4911   4912 49120    49121   49122    4918    4919     4912    49120    49121    49122 
 
-Bronchitis 
-Emphysema 
-Asthma 
-Bronchiectasis 
-Extrinsic allergic alveolitis 
-Chronic airway obstruction 
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APPENDIX D 
ICD-9 CODES TO IDENTIFY MENTAL HEALTH DISEASE 
 
296   2960   29600   29601   29602   29603   29604   29605   29606   2961   29611   29612   29613   29614   
29615 29616   2964   29640   29616   2964   29640   29641   29642  29643  29644  29645 29646 2965  
29650  29651 29652 29653  29654 29656 2966 29660 29662 29663  29664  29665  2967  300  3000  
30000  30001  30002  30009  30021  3003  3009  295  29500  30001  30002  30009 30021  3003 3009 295 
2950 29500  29501  29502  29503 29504 29505  2951 29510  29511 29512   29513   29515   2952   29520   
29521   29522   29523   29524   29525   2953   29530   29531   25932   29533  29534  29535  2954   29540   
29541  29542  29543  29544  29545 2955 29550  29551 29552 29553  29554  29555  2956  29561  29562  
29563  29564  29565  2957  29570  29571  29572 29573  29574  29575  2958  29580  29581  29582  
29583  29584  29585  2959  29591  29592  29593  29594  29595  
 
-Episodic mood disorders 
-Bipolar disorder 
-Manic disorder 
-Major depressive disorder 
-Schizophrenia 
-Anxiety 
-Phobic disorders 
-Somatoform disorders 
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APPENDIX E 
ANTIDEPRESSANT MEDICATIONS LIST 
 
 
 
 
 Selective Serotonin Reuptake Inhibitors Antidepressants (SSRIs)  
       Citalopram; Escitalopram; Fluoxetine; Fluvoxamine; Paroxetine; Sertraline  
 Selective Serotonin-Norepinephrine Reuptake Inhibitors Antidepressants (SSNRIs)  
Desvenlafaxine; Duloxetine; Venlafaxine;  
 Tetracyclic Antidepressants (TeCAs)  
Maprotiline; Mirtazapine; 
 Monoamine Oxidase Inhibitors (MAOIs) 
Isocarboxazid; Selegiline; Phenelzine; Tranylcypromine  
 Phenylpiperazine Antidepressants  
            Nefazodone; Trazodone 
 Psychotherapeutic combinations 
Amitriptyline-clordiazepoxide; Amitriptyline-perphenazine ; Fluoxetine-olanzapine; 
 Tricyclic antidepressants (TCAs) 
Amitriptyline; Amoxapine; Clomipramine; Desipramine; Doxepin; Imipramine;   
           Nortryptiline; Protryptyline; Trimipramine  
 Miscellaneous Antidepressants  
            Bupropion; Vilazodone 
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